Literature DB >> 7959274

Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability.

M Préfontaine1, A T Gelfand, J T Donovan, J L Powell.   

Abstract

We evaluated the accuracy and interobserver variability of intraoperative tumor measurements in ovarian cancer. Thirty-four obstetrician-gynecologists, 26 gynecologic oncologists, and 12 residents estimated the size of a primary ovarian cancer and four metastases in a simulated patient at laparotomy. The validity of the model was rated from 1 (poor) to 10 (excellent) as 6.9 +/- 1.3 (range 4-10). Actual diameters and range of estimates were, respectively, primary ovarian tumor, 13 cm and 4 to 20 cm; plaque right pelvic sidewall, 8.5 cm and 0 to 12 cm; paraaortic nodes, 2 cm and 0 to 5 cm; right hemidiaphragm, 1 cm and 0.3 to 3 cm; and left hemidiaphragm, 5 cm and 2 to 7 cm. There was no significant difference in measurements between the three groups of surgeons. More surgeons underestimated than overestimated tumor diameters. Tumor measurements in individual patients are highly variable; interpretation of the surgical literature and ovarian cancer treatment protocols based on tumor volume are subject to significant measurement error.

Entities:  

Mesh:

Year:  1994        PMID: 7959274     DOI: 10.1006/gyno.1994.1253

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer.

Authors:  Kimberly Fung; Sai Kiran Sharma; Outi Keinänen; Kara Long Roche; Jason S Lewis; Brian M Zeglis
Journal:  Mol Pharm       Date:  2020-07-16       Impact factor: 4.939

2.  Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.

Authors:  Irene A Burger; Debra A Goldman; Hebert Alberto Vargas; Michael W Kattan; Changhon Yu; Lei Kou; Vaagn Andikyan; Dennis S Chi; Hedvig Hricak; Evis Sala
Journal:  Gynecol Oncol       Date:  2015-06-17       Impact factor: 5.482

3.  Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.

Authors:  Satoyo Hosono; Hiroaki Kajiyama; Kimio Mizuno; Katsumi Sakakibara; Katsuji Matsuzawa; Akihiro Takeda; Michiyasu Kawai; Tetsuro Nagasaka; Fumitaka Kikkawa
Journal:  Int J Clin Oncol       Date:  2011-03-23       Impact factor: 3.402

4.  Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Ramez N Eskander; James Kauderer; Krishnansu S Tewari; Robert S Mannel; Robert E Bristow; David M O'Malley; Stephen C Rubin; Gretchen E Glaser; Chad A Hamilton; Keiichi Fujiwara; Warner K Huh; Frederick Ueland; Jean-Marie Stephan; Robert A Burger
Journal:  Gynecol Oncol       Date:  2018-03-15       Impact factor: 5.482

Review 5.  Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review.

Authors:  J Borley; C Wilhelm-Benartzi; R Brown; S Ghaem-Maghami
Journal:  Br J Cancer       Date:  2012-08-30       Impact factor: 7.640

6.  Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer.

Authors:  Ayaka Iura; Morihito Takita; Aiko Kawano; Kazuaki Imai; Katsuyuki Konnai; Ryo Onose; Hisamori Kato
Journal:  J Gynecol Oncol       Date:  2018-05-04       Impact factor: 4.401

7.  Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.

Authors:  Nienke Zwakman; Rafli van de Laar; Toon Van Gorp; Petra L M Zusterzeel; Marc P M L Snijders; Isabel Ferreira; Leon F A G Massuger; Roy F P M Kruitwagen
Journal:  J Gynecol Oncol       Date:  2016-09-12       Impact factor: 4.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.